TY - JOUR
T1 - Short-term effects of beraprost sodium on the markers for cardiovascular risk prediction in type 2 diabetic patients with microalbuminuria
AU - Choi, Yun Mi
AU - Kwon, Hyuk Sang
AU - Choi, Kyung Mook
AU - Lee, Won Young
AU - Hong, Eun Gyoung
N1 - Funding Information:
This study was supported by a Research Grant from Astellas Pharma Korea, Inc. (BER-DM 11-003). The funders had no role in study design, data collection and analysis, or preparation of the manuscript.
Publisher Copyright:
Copyright © 2019 Korean Endocrine Society.
PY - 2019/12/1
Y1 - 2019/12/1
N2 - Background: To evaluate the changes in cardiovascular risk markers including pulse wave velocity (PWV), microalbuminuria, inflammatory cytokines, and adhesion molecules after treatment with beraprost sodium (BPS) in patients with diabetic nephropathy Methods: This was a multicenter, prospective, randomized, double-blind, placebo-controlled trial. Type 2 diabetes mellitus patients with microalbuminuria were included. The primary endpoints were changes in microalbuminuria in spot urine and PWV after BPS or placebo (PCB) treatment for 24 weeks. The secondary endpoints were changes in clinical and metabolic parameters. Results: A total of 52 patients completed the 24-week trial. Changes in PWV were not different significantly in the BPS and PCB groups (right, P=0.16; left, P=0.11). Changes in microalbuminuria were 14.2±157.0 and 34.5±146.6 (μg/mg Cr) in the BPS and PCB groups, respectively (P=0.63). Subgroup analysis in the high blood pressure (BP) group (baseline systolic BP >120 mm Hg and diastolic BP >80 mm Hg), showed that microalbuminuria decreased by –47.6 in the BPS group compared with an increase by 116.4 (μg/mg Cr) in the PCB group (P=0.04). Also, in the large waist circumference group (>95 cm), microalbuminuria decreased significantly in the BPS group (P=0.04). Conclusion: Short-term treatment of BPS for patients with diabetic nephropathy did not show significant improvement in various cardiovascular risk factors. However, BPS significantly decreased microalbuminuria in study subjects with higher cardiovascular risk such as high BP or large waist circumference.
AB - Background: To evaluate the changes in cardiovascular risk markers including pulse wave velocity (PWV), microalbuminuria, inflammatory cytokines, and adhesion molecules after treatment with beraprost sodium (BPS) in patients with diabetic nephropathy Methods: This was a multicenter, prospective, randomized, double-blind, placebo-controlled trial. Type 2 diabetes mellitus patients with microalbuminuria were included. The primary endpoints were changes in microalbuminuria in spot urine and PWV after BPS or placebo (PCB) treatment for 24 weeks. The secondary endpoints were changes in clinical and metabolic parameters. Results: A total of 52 patients completed the 24-week trial. Changes in PWV were not different significantly in the BPS and PCB groups (right, P=0.16; left, P=0.11). Changes in microalbuminuria were 14.2±157.0 and 34.5±146.6 (μg/mg Cr) in the BPS and PCB groups, respectively (P=0.63). Subgroup analysis in the high blood pressure (BP) group (baseline systolic BP >120 mm Hg and diastolic BP >80 mm Hg), showed that microalbuminuria decreased by –47.6 in the BPS group compared with an increase by 116.4 (μg/mg Cr) in the PCB group (P=0.04). Also, in the large waist circumference group (>95 cm), microalbuminuria decreased significantly in the BPS group (P=0.04). Conclusion: Short-term treatment of BPS for patients with diabetic nephropathy did not show significant improvement in various cardiovascular risk factors. However, BPS significantly decreased microalbuminuria in study subjects with higher cardiovascular risk such as high BP or large waist circumference.
KW - Beraprost
KW - Diabetic nephropathies
KW - Vascular stiffness
UR - http://www.scopus.com/inward/record.url?scp=85078454998&partnerID=8YFLogxK
U2 - 10.3803/EnM.2019.34.4.398
DO - 10.3803/EnM.2019.34.4.398
M3 - Article
C2 - 31884740
AN - SCOPUS:85078454998
SN - 2093-596X
VL - 34
SP - 398
EP - 405
JO - Endocrinology and Metabolism
JF - Endocrinology and Metabolism
IS - 4
ER -
